2022
Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota
Petrone ME, Rothman JE, Breban MI, Ott IM, Russell A, Lasek-Nesselquist E, Badr H, Kelly K, Omerza G, Renzette N, Watkins AE, Kalinich CC, Alpert T, Brito AF, Earnest R, Tikhonova IR, Castaldi C, Kelly JP, Shudt M, Plitnick J, Schneider E, Murphy S, Neal C, Laszlo E, Altajar A, Pearson C, Muyombwe A, Downing R, Razeq J, Niccolai L, Wilson MS, Anderson ML, Wang J, Liu C, Hui P, Mane S, Taylor BP, Hanage WP, Landry ML, Peaper DR, Bilguvar K, Fauver JR, Vogels CBF, Gardner LM, Pitzer VE, St. George K, Adams MD, Grubaugh ND. Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. Communications Biology 2022, 5: 439. PMID: 35545661, PMCID: PMC9095641, DOI: 10.1038/s42003-022-03347-3.Peer-Reviewed Original ResearchTuberculosis attributed to transmission within healthcare facilities, Botswana—The Kopanyo Study
Smith JP, Modongo C, Moonan PK, Dima M, Matsiri O, Fane O, Click ES, Boyd R, Finlay A, Surie D, Tobias JL, Zetola NM, Oeltmann JE. Tuberculosis attributed to transmission within healthcare facilities, Botswana—The Kopanyo Study. Infection Control And Hospital Epidemiology 2022, 43: 1603-1609. PMID: 35382909, PMCID: PMC9535034, DOI: 10.1017/ice.2021.517.Peer-Reviewed Original ResearchConceptsElectronic medical recordsHealthcare facilitiesPopulation-based molecular epidemiologic studyMolecular epidemiologic studiesTB casesTB diagnosisTB transmissionTB epidemicMedical recordsTuberculosis diseaseBiologic plausibilityHealthcare workersIndividual patientsEpidemiologic studiesGeneral populationCommunity transmissionEtiologic agentTreatment dataClinical encountersPatientsEffective interventionsIndividual riskEMR dataTransmission eventsHigh-risk environmentsThe required size of cluster randomized trials of nonpharmaceutical interventions in epidemic settings
Sheen J, Haushofer J, Metcalf C, Kennedy‐Shaffer L. The required size of cluster randomized trials of nonpharmaceutical interventions in epidemic settings. Statistics In Medicine 2022, 41: 2466-2482. PMID: 35257398, PMCID: PMC9111156, DOI: 10.1002/sim.9365.Peer-Reviewed Original ResearchConceptsCluster randomized trialEffectiveness of interventionsSample sizeRandomized trialsPlanning such trialsApproximate sample size formulaeReduce transmissionEffect sizeNonpharmaceutical interventionsInfectious disease outbreaksObservational studyInterventionEpidemic settingsSample size methodsAdequate powerSARS-CoV-2 pandemicSARS-CoV-2 transmissionSample size formulaTested individualsSimulated bankTreatment effectsTrialsCommunity transmissionOutbreak settingsSize formulaDevelopment and Application of a Polydimethylsiloxane-Based Passive Air Sampler to Assess Personal Exposure to SARS-CoV‑2
Angel D, Gao D, DeLay K, Lin E, Eldred J, Arnold W, Santiago R, Redlich C, Martinello R, Sherman J, Peccia J, Pollitt K. Development and Application of a Polydimethylsiloxane-Based Passive Air Sampler to Assess Personal Exposure to SARS-CoV‑2. Environmental Science & Technology Letters 2022, 9: 153-159. PMID: 37566382, PMCID: PMC11783850, DOI: 10.1021/acs.estlett.1c00877.Peer-Reviewed Original ResearchSARS-CoV-2Personal exposureAirborne SARS-CoV-2 RNASARS-CoV-2 exposureHigh-risk transmission areasSARS-CoV-2 RNAInfection control protocolsHigh-risk settingsVirus-laden aerosolsRespiratory virusesViral exposurePassive samplersExposure assessment toolsCommunity transmissionRespiratory dropletsInfectious virusEarly detectionViral loadingTransmission areasViral concentrationElectrical powerCOVID-19RNA/VirusDrum experiments
2021
Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA
Omer SB, Benjamin RM, Brewer NT, Buttenheim AM, Callaghan T, Caplan A, Carpiano RM, Clinton C, DiResta R, Elharake JA, Flowers LC, Galvani AP, Lakshmanan R, Maldonado YA, McFadden SM, Mello MM, Opel DJ, Reiss DR, Salmon DA, Schwartz JL, Sharfstein JM, Hotez PJ. Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. The Lancet 2021, 398: 2186-2192. PMID: 34793741, PMCID: PMC8592561, DOI: 10.1016/s0140-6736(21)02507-1.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineSARS-CoV-2 infectionCOVID-19 vaccination campaignCOVID-19 vaccine acceptanceCOVID-19 vaccine programPfizer-BioNTech vaccineEmergency use authorisationVaccine programVaccine acceptanceVaccination campaignVaccine refusalCommunity transmissionUS FoodDrug AdministrationInadequate uptakeVaccineBehavioral intervention strategiesBest interventionLancet CommissionLow uptakeIntervention strategiesCOVID-19Evidence-based educationFull approvalUS residentsAntibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
Althoff K, Schlueter D, Anton-Culver H, Cherry J, Denny J, Thomsen I, Karlson E, Havers F, Cicek M, Thibodeau S, Pinto L, Lowy D, Malin B, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Roman A, Sharpless N, Gebo K, Schully S. Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020. Clinical Infectious Diseases 2021, 74: 584-590. PMID: 34128970, PMCID: PMC8384413, DOI: 10.1093/cid/ciab519.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayBlood specimensSARS-CoV-2 enzyme-linked immunosorbent assaySARS-CoV-2 immunoglobulin G (IgG) antibodiesSARS-CoV-2 antibodiesIgG enzyme-linked immunosorbent assayConfidence intervalsImmunoglobulin G antibodiesSARS-CoV-2Sequential testing algorithmEUROIMMUN assaysSymptomatic patientsTesting algorithmStudy visitG antibodiesCommunity transmissionTravel historyStudy participantsUS epidemicEarly weeksImmunosorbent assayTesting capacityAntibodiesWeeksUS statesUtility of Mass SARS-CoV-2 Testing of Asymptomatic Patients Before Ambulatory and Inpatient Preplanned Procedures Requiring Moderate Sedation or General Anesthesia
Roberts SC, Peaper DR, Sussman LS, Martinello RA, Pettker CM. Utility of Mass SARS-CoV-2 Testing of Asymptomatic Patients Before Ambulatory and Inpatient Preplanned Procedures Requiring Moderate Sedation or General Anesthesia. JAMA Network Open 2021, 4: e2114526. PMID: 34170307, PMCID: PMC8233702, DOI: 10.1001/jamanetworkopen.2021.14526.Peer-Reviewed Original ResearchClinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. Annals Of Internal Medicine 2021, 174: 803-810. PMID: 33683930, PMCID: PMC9317280, DOI: 10.7326/m21-0510.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Antigen testingHome testingSARS-CoV-2 antigen testingIncremental cost-effectiveness ratioSARS-CoV-2 transmissionCost-effectiveness ratioBase-case analysisRapid testingPrevention guidanceDeath avertedDisease progressionInpatient careCommunity transmissionOutcome estimatesTesting interventionsViral transmissionDisease controlInfectionNumber of personsCumulative infectionsNational containment strategyWarrants considerationU.S. populationDeathProtective impacts of household-based tuberculosis contact tracing are robust across endemic incidence levels and community contact patterns
Havumaki J, Cohen T, Zhai C, Miller JC, Guikema SD, Eisenberg MC, Zelner J. Protective impacts of household-based tuberculosis contact tracing are robust across endemic incidence levels and community contact patterns. PLOS Computational Biology 2021, 17: e1008713. PMID: 33556077, PMCID: PMC7895355, DOI: 10.1371/journal.pcbi.1008713.Peer-Reviewed Original ResearchConceptsTuberculosis burdenCommunity transmissionGlobal tuberculosis control targetsSustained community transmissionHigh-incidence settingsHigh disease burdenTuberculosis contact tracingLow tuberculosis burdenHousehold contactsHousehold transmissionDisease burdenVaried incidenceContact patternsIncidence levelsProtective impactEpidemiological settingsInfected individualsNew casesProtective benefitsContact tracingCommunity contactsSuch interventionsInterventionBurdenProactive casePublic health actions to control new SARS-CoV-2 variants
Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants. Cell 2021, 184: 1127-1132. PMID: 33581746, PMCID: PMC7846239, DOI: 10.1016/j.cell.2021.01.044.Peer-Reviewed Original Research
2020
Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events
Lemieux JE, Siddle KJ, Shaw BM, Loreth C, Schaffner SF, Gladden-Young A, Adams G, Fink T, Tomkins-Tinch CH, Krasilnikova LA, DeRuff KC, Rudy M, Bauer MR, Lagerborg KA, Normandin E, Chapman SB, Reilly SK, Anahtar MN, Lin AE, Carter A, Myhrvold C, Kemball ME, Chaluvadi S, Cusick C, Flowers K, Neumann A, Cerrato F, Farhat M, Slater D, Harris JB, Branda JA, Hooper D, Gaeta JM, Baggett TP, O'Connell J, Gnirke A, Lieberman TD, Philippakis A, Burns M, Brown CM, Luban J, Ryan ET, Turbett SE, LaRocque RC, Hanage WP, Gallagher GR, Madoff LC, Smole S, Pierce VM, Rosenberg E, Sabeti PC, Park DJ, MacInnis BL. Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events. Science 2020, 371: eabe3261. PMID: 33303686, PMCID: PMC7857412, DOI: 10.1126/science.abe3261.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Sustained community transmissionSyndrome coronavirus 2Skilled nursing facilitiesSARS-CoV-2Coronavirus 2Nursing facilitiesCommunity transmissionCommunity spreadSignificant mortalityVulnerable populationsGenomic epidemiologyTransmission dynamicsPhylogenetic analysisGenetic variationNumerous introductionsInternational spreadRapid transmissionThe Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society
Rubin G, Ryerson C, Haramati L, Sverzellati N, Kanne J, Raoof S, Schluger N, Volpi A, Yim J, Martin I, Anderson D, Kong C, Altes T, Bush A, Desai S, Goldin J, Goo J, Humbert M, Inoue Y, Kauczor H, Luo F, Mazzone P, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop C, Tomiyama N, Wells A, Leung A. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology 2020, 296: 201365. PMID: 32255413, PMCID: PMC7233395, DOI: 10.1148/radiol.2020201365.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRisk factorsChest radiographyCOVID-19Upper respiratory viral infectionRespiratory viral infectionsCoronavirus disease 2019 (COVID-19) pandemicUnprecedented health care crisisHealth care workersDisease 2019 pandemicPersonal protective equipmentHealth care deliveryPulmonary disease diagnosisHospitalized patientsRespiratory dysfunctionDisease progressionMild casesMultidisciplinary panelPretest probabilityChest imagingConsensus statementPatient managementRespiratory diseaseSevere casesCommunity transmissionViral infectionThe Role of Chest Imaging in Patient Management During the COVID-19 Pandemic A Multinational Consensus Statement From the Fleischner Society
Rubin G, Ryerson C, Haramati L, Sverzellati N, Kanne J, Raoof S, Schluger N, Volpi A, Yim J, Martin I, Anderson D, Kong C, Altes T, Bush A, Desai S, Goldin J, Goo J, Humbert M, Inoue Y, Kauczor H, Luo F, Mazzone P, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop C, Tomiyama N, Wells A, Leung A. The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic A Multinational Consensus Statement From the Fleischner Society. CHEST Journal 2020, 158: 106-116. PMID: 32275978, PMCID: PMC7138384, DOI: 10.1016/j.chest.2020.04.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRisk factorsChest radiographyCOVID-19Upper respiratory viral infectionRespiratory viral infectionsCoronavirus disease 2019 (COVID-19) pandemicUnprecedented health care crisisHealth care workersDisease 2019 pandemicPersonal protective equipmentHealth care deliveryPulmonary disease diagnosisHospitalized patientsRespiratory dysfunctionDisease progressionMild casesMultidisciplinary panelPretest probabilityChest imagingConsensus statementPatient managementRespiratory diseaseSevere casesCommunity transmissionViral infection
2016
Retrospective Analysis of the 2014-2015 Ebola Epidemic in Liberia.
Atkins KE, Pandey A, Wenzel NS, Skrip L, Yamin D, Nyenswah TG, Fallah M, Bawo L, Medlock J, Altice FL, Townsend J, Ndeffo-Mbah ML, Galvani AP. Retrospective Analysis of the 2014-2015 Ebola Epidemic in Liberia. American Journal Of Tropical Medicine And Hygiene 2016, 94: 833-9. PMID: 26928839, PMCID: PMC4824226, DOI: 10.4269/ajtmh.15-0328.Peer-Reviewed Original ResearchConceptsCommunity transmissionEbola epidemicHospital transmissionAsymptomatic infectionImmune individualsRetrospective analysisEpidemiological dataUnreported casesDisease controlEbola dynamicsHospital capacityEpidemic patternsEbola incidenceFuture outbreaksPresence of interventionsEpidemicLiberian countiesTransmission reductionInfectionDiseaseIncidence
2015
Prisons as Reservoir for Community Transmission of Tuberculosis, Brazil - Volume 21, Number 3—March 2015 - Emerging Infectious Diseases journal - CDC
Sacchi FP, Praça RM, Tatara MB, Simonsen V, Ferrazoli L, Croda MG, Suffys PN, Ko AI, Andrews JR, Croda J. Prisons as Reservoir for Community Transmission of Tuberculosis, Brazil - Volume 21, Number 3—March 2015 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2015, 21: 452-455. PMID: 25642998, PMCID: PMC4344267, DOI: 10.3201/eid2103.140896.Peer-Reviewed Original ResearchThe contribution of extended-spectrum &bgr;-lactamases to multidrug-resistant infections in children
Murray TS, Peaper DR. The contribution of extended-spectrum &bgr;-lactamases to multidrug-resistant infections in children. Current Opinion In Pediatrics 2015, 27: 124-131. PMID: 25565574, DOI: 10.1097/mop.0000000000000182.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial Agentsbeta-Lactam Resistancebeta-LactamasesChildChild, PreschoolCommunity-Acquired InfectionsCross InfectionDrug Resistance, MultipleEscherichia coliEscherichia coli InfectionsGram-Negative Bacterial InfectionsHumansInfantKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsPrevalenceConceptsMultidrug-resistant infectionsGram-negative rodsProlonged fecal carriageAntibiotic prescribing practicesPrevious antibiotic useExtended-spectrum β-lactamasesCommon risk factorsThird-generation cephalosporinsDiagnostic toolAppropriate therapyChallenging infectionsPrescribing practicesNeonatal ICULaboratory criteriaNew diagnostic toolsRisk factorsAntibiotic useFecal carriageCommunity transmissionClinical implicationsInfectionCephalosporin resistanceKlebsiella pneumoniaeReporting criteriaΒ-lactamases
2011
Epidemiologic Inference From the Distribution of Tuberculosis Cases in Households in Lima, Peru
Brooks-Pollock E, Becerra MC, Goldstein E, Cohen T, Murray MB. Epidemiologic Inference From the Distribution of Tuberculosis Cases in Households in Lima, Peru. The Journal Of Infectious Diseases 2011, 203: 1582-1589. PMID: 21592987, PMCID: PMC3096792, DOI: 10.1093/infdis/jir162.Peer-Reviewed Original ResearchConceptsHousehold contactsCommunity transmissionHousehold casesPrevious TB infectionNew TB casesHigh-incidence settingsHousehold risk factorsClustering of casesDistribution of casesMajority of casesRisk of diseaseTB infectionActive tuberculosisTB casesCase patientsProtective immunityTuberculosis casesHousehold transmissionRisk factorsNumber of casesHousehold exposureNatural historyTuberculosisCross-sectional dataImmunity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply